Chronic Kidney Disease | Treatment Algorithms: Claims Data Analysis | US | 2025
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive agents and SGLT-2 inhibitors, which are intended to delay disease progression. RAAS inhibitors are the standard-of-care therapy for CKD. SGLT-2 inhibitors, primarily Jardiance and Farxiga, are rapidly becoming the preferred treatments for CKD, owing to their approval for use in all CKD patients, regardless of diabetes status. Finerenone (Bayer’s Kerendia), a novel nonsteroidal selective mineralocorticoid receptor antagonist (MRA), and semaglutide (Novo Nordisk’s Ozempic), a GLP-1 receptor agonist, are both approved for treating diabetic kidney disease. This report provides insights into how the key drug classes for CKD treatment are used in newly diagnosed and recently treated CKD patients.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CKD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed patients?
- How has semaglutide been integrated into the treatment algorithm, and what is its source of business?
- What percentage of CKD patients receive drug therapy within 365 of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 of diagnosis?
- What percentage of CKD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Real-world data: Patient-level claims data analysis
Key drugs covered: RAAS inhibitors, dapagliflozin, empagliflozin, finerenone, semaglutide
Key analyses: Brand / therapy usage across patient sample; Newly diagnosed patient analysis; Treatment initiation and progression; Line of therapy analysis; Combination therapy analysis; Source of business for recently treated patients; Persistency and compliance analysis; Product-level patient flow
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
